Avexa Limited  

(Public, ASX:AVX)   Watch this stock  
Find more results for Mitchell M. Cox�
0.0000 (0.00%)
Aug 28 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.01 - 0.01
52 week 0.01 - 0.03
Open 0.01
Vol / Avg. 767,658.00/436,346.00
Mkt cap 7.85M
P/E     -
Div/yield     -
EPS 0.00
Shares 925.65M
Beta     -
Inst. own     -

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -6500.00% -982.03%
Operating margin -9400.00% -1085.76%
EBITD margin - -872.88%
Return on average assets -13.17% -22.34%
Return on average equity -13.69% -23.17%
Employees 5 -
CDP Score - -


Suite 8, Level 1 61-63 Camberwell Road Hawthorn East
+61-3-88881040 (Phone)
+61-3-88881049 (Fax)

Website links


Avexa Limited (Avexa) is an Australia-based biotechnology company with a focus on discovery, development and commercialization of small molecules for the treatment of infectious diseases. Avexa’s projects include apricitabine (ATC) for the treatment of drug resistant HIV, an HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections. The Company operates in two segments: Research and Development, the operation of conducting research and development for commercialization, of anti-infective pharmaceutical programs and projects, and Investments, investing in the United States coal mine and the Australian equities. Apricitabine (ATC) is Avexa’s nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of human immunodeficiency virus (HIV) infection.

Officers and directors

Jonathan Coates Interim Chief Executive Officer, Chief Scientific Officer
M. Klapakis Financial Controller
Susan W. Cox Head of Drug Development
Lee Mitchell Company Secretary
Iain M. C. Kirkwood CPA Independent Non-Executive Chairman of the Board
Age: 62
Bruce Hewett Independent Non-Executive Director
Age: 59
Allan Tan Independent Non-Executive Director
Age: 48